SRT

Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold

Retrieved on: 
星期四, 五月 9, 2024
Knowledge, Keloid, Sale, American Academy, Far Eastern Memorial Hospital, Vision system, Conference call, Research, Depreciation, Traction, Dermatology, Conference, SRT, Cat, Patient safety, Tax, Patent, Patient, Fair Deal, Neoplasm, Inflammation, Marketing, Dog, Adjustment, Vision, GAAP, Growth, Pharmaceutical industry

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three months ended March 31, 2024.

Key Points: 
  • Revenues for the first quarter of 2024 were $10.7 million, compared with $3.4 million for the first quarter of 2023, an increase of $7.3 million, or 215%.
  • Other income of $0.2 million for the first quarter of 2024 was mostly related to interest income, and was unchanged from the prior-year quarter.
  • Adjusted EBITDA for the first quarter of 2024 was $3.0 million, compared with negative $2.7 million for the first quarter of 2023.
  • Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare.

Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare’s SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats

Retrieved on: 
星期四, 五月 9, 2024
Knowledge, Sale, Fort Collins, Colorado, Radiation, Animal, Colorado State University, Beit Berl College, Turtle, SRT, Cat, Veterinary medicine, Patient, Emergency, Neoplasm, Dog, Bird, CSU, Horse, Medical imaging

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of an SRT-100 system to Chavat Da’at, the Veterinary Specialist Referral Center Knowledge Farm at Beit Verl College in Tel Aviv, to provide a gentler radiotherapy option to treat tumors in dogs and cats. This is the first commercial sale of the SRT-100 for veterinary use outside the U.S.

Key Points: 
  • Soon thereafter, an Emergency and Critical Care Center was established, which operates 24 hours a day.
  • Knowledge Farm is the largest private Veterinary Specialty Referral Center in Israel with more than 20 board-certified specialists and emergency physicians, and more than 30 qualified veterinary technicians and support staff.
  • “Whether for treating small animals like cats, dogs, turtles and birds, or large ones like horses, our technology is a valuable addition to leading veterinary practices worldwide.
  • These leaders are exploring and expanding the veterinary indications for radiotherapy, while making treatments increasingly available and affordable to many more pet owners,” he added.

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting

Retrieved on: 
星期四, 五月 9, 2024
FDA, Bone marrow, Mutation, Cell, Risk, Blood, News, Research, ERT, White blood cell, Glycogen storage disease, SRT, ALT, GBA1, White, European Medicines Agency, Brain, Enzyme replacement therapy, Regenerative Medicine Advanced Therapy, Therapy, Plasma, Patient, Mouse, Safety, Tissue, Glucocerebrosidase, Substantia nigra, Lysosome, Neuropsychological test, AAV, Dementia, PRIME, Fatigue, EMA, Drug development, Bone pain, Gaucher's disease, FACIT, Disease, Liver, Gene, Society, Standard of care, Annual general meeting, Pharmaceutical industry

LONDON, May 09, 2024 (GLOBE NEWSWIRE) --  Freeline Therapeutics today announced new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease, showing substantial reductions in glucosylsphinogsine (lyso-Gb1), one of the best predictors of clinical response, in patients with persistently high levels despite years of treatment with currently approved therapies, as well as early signs of clinical improvements in bone marrow burden and fatigue. FLT201 continues to demonstrate a favorable safety and tolerability profile. These data are being showcased in a late-breaking oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, Maryland.

Key Points: 
  • These data are being showcased in a late-breaking oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, Maryland.
  • Reductions in lyso-Gb1 levels in the blood are highly correlated with substrate reduction in disease-affected tissues and positive clinical outcomes in Gaucher disease.
  • Currently approved treatments have made a significant difference for people with Gaucher disease, but there is not an existing cure.
  • Both the late-breaking oral presentation and the poster presentation are now available on the News & Events section of Freeline’s website.

Survey Shows Stark Difference in Satisfaction Rates Among Skin Cancer Patients Treated Surgically and Nonsurgically

Retrieved on: 
星期三, 五月 1, 2024
Pain, Mohs surgery, Skin, Risk, Private practice, Commonwealth, Dermatology, Skin cancer, SRT, Patient, Medical imaging

The survey involved 3,915 individuals who had been treated for nonmelanoma skin cancer one or more times.

Key Points: 
  • The survey involved 3,915 individuals who had been treated for nonmelanoma skin cancer one or more times.
  • SkinCure Oncology Chief Executive Officer Kerwin Brandt explained, "With GentleCure, we're providing cancer center level of care in the private practice.
  • Dermatologists across the country are celebrating the introduction of this nonsurgical treatment for the nation's most common cancer type – nonmelanoma skin cancer.
  • While May is Skin Cancer Awareness Month, early-adopter skin specialists in 40 states are already providing the GentleCure Experience to patients who prefer to avoid surgery or for whom surgery is not recommended.

Haivision Celebrates 20 Years of Leadership and Innovation in Live Video

Retrieved on: 
星期三, 五月 1, 2024
SpaceX, Salesforce, HAI, RBC, NASA, TSX, Fox Sports, SRT, Engineering, NASCAR, Toronto Stock Exchange, Microsoft, NHL, Government, Video game

MONTREAL, May 1, 2024 /PRNewswire/ - Haivision Systems Inc. ("Haivision") (TSX: HAI), a leading global provider of mission-critical, real-time video networking and visual collaboration solutions, is proud to announce its 20th anniversary – a significant milestone that highlights the company's leadership and innovation in mission-critical, live video solutions.

Key Points: 
  • MONTREAL, May 1, 2024 /PRNewswire/ - Haivision Systems Inc. ("Haivision") (TSX: HAI), a leading global provider of mission-critical, real-time video networking and visual collaboration solutions, is proud to announce its 20th anniversary – a significant milestone that highlights the company's leadership and innovation in mission-critical, live video solutions.
  • Over the past two decades, Haivision has revolutionized the way video is used for mission-critical applications, with a focus on security, reliability, performance, and quality.
  • These milestones reflect Haivision's dedication to excellence and its role as a trusted provider of mission-critical video solutions.
  • "Twenty years ago, we set out to change the real-time, low-latency, live video networking landscape," said Mirko Wicha, Founder and CEO of Haivision.

Dermatology Association of Radiation Therapy (DART) Opposes Move to Cancel Medicare Coverage for Nonsurgical Treatment of Nonmelanoma Skin Cancer in Seven States

Retrieved on: 
星期一, 四月 29, 2024
Education, Keloid, LCD, American Academy, Radiation, NCCN, Mohs surgery, Carcinoma, Policy, Skin, DART, National Comprehensive Cancer Network, American Academy of Dermatology, Recurrence, Research, SCC, Comment, Doctor of Philosophy, SRT, Radiation therapy, Documentation, NMSC, Patient, Treatment, Society, AAD, RT, BCC, ASTRO, Health insurance

The proposed LCD at issue, DL39808 " Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) ," would affect residents in North and South Carolina, Virginia, West Virginia, Alabama, Georgia and Tennessee.

Key Points: 
  • The proposed LCD at issue, DL39808 " Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) ," would affect residents in North and South Carolina, Virginia, West Virginia, Alabama, Georgia and Tennessee.
  • The DART filing noted, "In its current form, the LCD is fundamentally misdirected, misguided, and inappropriate.
  • It would altogether remove any semblance of patient choice or physician clinical decision making for patients who are diagnosed with NMSC.
  • At the outset, DART underscores that the proposed LCD was filed as a Medicare Part A policy.

Backlight Announces Availability of Zype Playout in AWS Marketplace

Retrieved on: 
星期三, 五月 1, 2024
Software, Technology, Audio, Video, PAW Patrol, Amazon Web Services, Social media, Backlight, Samsung Electronics, FAST, FastPass, Playout, SRT, Fingerboard (skateboard), Roku, Pluto TV, WJZ, OTT, Zixi County, AWS, Samsung, Video game

Global media and entertainment technology company, Backlight, today announced that its cloud-based linear playout solution, Zype Playout is now available in AWS Marketplace, a digital catalog with thousands of software listings from independent software vendors (ISVs) that make it easy to find, test, buy, and deploy software that runs on Amazon Web Services (AWS).

Key Points: 
  • Global media and entertainment technology company, Backlight, today announced that its cloud-based linear playout solution, Zype Playout is now available in AWS Marketplace, a digital catalog with thousands of software listings from independent software vendors (ISVs) that make it easy to find, test, buy, and deploy software that runs on Amazon Web Services (AWS).
  • With Zype Playout, AWS customers can now rapidly build and deliver streaming video channels through Backlight’s easy-to-use cloud-based platform.
  • Now that it is available in AWS Marketplace, customers will be able to easily extend their video workflows with Backlight’s robust cloud-playout solution.
  • “We are excited to be able to integrate Backlight’s solution in a deeper way via AWS Marketplace.”
    Learn more about Zype Playout in AWS Marketplace and how to deploy it, here .

Heidelberg Engineering Showcases the Future of Imaging, Extending Its Capabilities With a Breadth of Research Technology

Retrieved on: 
星期二, 四月 30, 2024
Technology, Biotechnology, Health, Apps, Applications, Surgery, Optical, Artificial Intelligence, Research, Medical Devices, General Health, Health Technology, Science, Data Management, Clinical Trials, FDA, University, IOL, DICOM, AI, Bausch & Lomb, Biostatistics, Artificial intelligence, 3D, SRT, OCT, Algorithm, Epithelium, Corneal topography, Google Images, ARVO, ETM, Tomography, Medical imaging

For the first time, Heidelberg Engineering will demonstrate the future of digital imaging with its investigational SEELUMA, developed and manufactured by Heidelberg Engineering subsidiary, Munich Surgical Imaging and distributed exclusively by Bausch + Lomb.

Key Points: 
  • For the first time, Heidelberg Engineering will demonstrate the future of digital imaging with its investigational SEELUMA, developed and manufactured by Heidelberg Engineering subsidiary, Munich Surgical Imaging and distributed exclusively by Bausch + Lomb.
  • The groundbreaking, fully digital, surgical-visualization platform features next-generation image technology with state-of-the-art intraoperative OCT that will transform the modern OR.
  • "In 2025, Heidelberg Engineering is set to revolutionize basic vision science with the introduction of the Heidelberg CHAMELEON Imaging Research Platform," said Heidelberg Engineering Clinical Development Manager — Investigational Technologies, Dr. Sebastian Rausch.
  • Monday night, Heidelberg Engineering will host an award presentation for the winner of the Heidelberg Engineering Xtreme Research Award that recognizes aspiring researchers for their outstanding contribution to ophthalmic research.

Blackmagic Design Announces New Blackmagic URSA Cine 12K

Retrieved on: 
星期五, 四月 12, 2024
Entertainment, Social Media, Film & Motion Pictures, Hardware, Events, Concerts, Consumer Electronics, Technology, Publishing, TV and Radio, Photography, Audio, Video, Communications, Cloud, CFexpress, LCD, Science, Metadata, Architecture, Internet, DaVinci Resolve, Glass, Urinary tract infection, Skin, Blackmagic URSA, SRT, Lens, OLPF, OLED, Black Magic, Tax, RGBW, EF, Cloud storage, IDX, Blackmagic Design, Hasselblad, Multimedia, XLR, TB, RTMP, LPL, Camera

Blackmagic URSA Cine 12K is available immediately from Blackmagic Design resellers worldwide from US$14,995.

Key Points: 
  • Blackmagic URSA Cine 12K is available immediately from Blackmagic Design resellers worldwide from US$14,995.
  • (Photo: Business Wire)
    The Blackmagic URSA Cine 12K will be demonstrated on the Blackmagic Design NAB 2024 booth #SL5005.
  • Blackmagic URSA Cine 12K is available now from US$14,995, excluding local duties and taxes, from Blackmagic Design resellers worldwide.
  • Product photos of the Blackmagic URSA Cine 12K, as well as all other Blackmagic Design products, are available at www.blackmagicdesign.com/media/images .

Blackmagic Design Announces New Blackmagic PYXIS 6K

Retrieved on: 
星期五, 四月 12, 2024
Technology, Photography, Audio, Video, Social Media, Entertainment, Online, Events, Concerts, Film & Motion Pictures, Influencer, Other Entertainment, Communications, TV and Radio, Hardware, Consumer Electronics, Cloud, CFexpress, LCD, Internet access, Internet, DaVinci Resolve, Glass, CNC, WB, Digital single-lens reflex camera, Android, ARRI, HDMI, Panasonic, SDI, Ultra, ISO, SRT, Sigma, Lens, OLED, Black Magic, Super 35, Solid-state drive, HDR, EF, Noise, Blackmagic Design, Multimedia, SSD, Apple, DCI, XLR, NAB, RTMP

Blackmagic PYXIS 6K will be available in June from Blackmagic Design resellers worldwide from US$2,995.

Key Points: 
  • Blackmagic PYXIS 6K will be available in June from Blackmagic Design resellers worldwide from US$2,995.
  • (Photo: Business Wire)
    The Blackmagic PYXIS 6K will be demonstrated on the Blackmagic Design NAB 2024 booth #SL5005.
  • Blackmagic PYXIS 6K will be available in June from US$2,995, excluding duties, from Blackmagic Design resellers worldwide.
  • Product photos of the Blackmagic PYXIS 6K, as well as all other Blackmagic Design products, are available at www.blackmagicdesign.com/media/images .